Abstract
Erectile dysfunction (ED) is often associated with cardiovascular disease (CVD) and the risk of sildenafilinduced orthostatic hypotension (OH) in subjects with CVD is a matter of concern. We describe our experience in using the tilt test (TT) with continuous plethysmography to evaluate the occurrence of OH in patients with CVD and ED after a test dose of sildenafil. When sildenafil was added on top of their usual pharmacological treatment two patients out of 32 (6.2%) developed asymptomatic OH, with a maximum blood pressure fall of 40/20 mm Hg. The low prevalence and modest clinical relevance of OH in our high-risk population coupled with the known high sensitivity and reproducibility of the TT seem to suggest that sildenafil is haemodynamically safer than is generally believed even when added on top of vasoactive treatment. These findings should be put into perspective against the growing wealth of evidence that PDE5 inhibitors may have therapeutic potential for a number of CV conditions.
Keywords: Erectile disfunction, sildenafil, orthostatic hypotension, drug safety, cardiovascular disease, Tilt Test, Plethysmography, PDE5 inhibitors
Current Drug Safety
Title: Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report
Volume: 6 Issue: 4
Author(s): M. M. Ciulla, P. Nicolini, C. Benfenati, C. Vecchiato, G. Acquistapace, G. L. Perrucci and F. Magrini
Affiliation:
Keywords: Erectile disfunction, sildenafil, orthostatic hypotension, drug safety, cardiovascular disease, Tilt Test, Plethysmography, PDE5 inhibitors
Abstract: Erectile dysfunction (ED) is often associated with cardiovascular disease (CVD) and the risk of sildenafilinduced orthostatic hypotension (OH) in subjects with CVD is a matter of concern. We describe our experience in using the tilt test (TT) with continuous plethysmography to evaluate the occurrence of OH in patients with CVD and ED after a test dose of sildenafil. When sildenafil was added on top of their usual pharmacological treatment two patients out of 32 (6.2%) developed asymptomatic OH, with a maximum blood pressure fall of 40/20 mm Hg. The low prevalence and modest clinical relevance of OH in our high-risk population coupled with the known high sensitivity and reproducibility of the TT seem to suggest that sildenafil is haemodynamically safer than is generally believed even when added on top of vasoactive treatment. These findings should be put into perspective against the growing wealth of evidence that PDE5 inhibitors may have therapeutic potential for a number of CV conditions.
Export Options
About this article
Cite this article as:
M. Ciulla M., Nicolini P., Benfenati C., Vecchiato C., Acquistapace G., L. Perrucci G. and Magrini F., Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report, Current Drug Safety 2011; 6 (4) . https://dx.doi.org/10.2174/157488611798280898
DOI https://dx.doi.org/10.2174/157488611798280898 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer’s Disease
Current Medicinal Chemistry Design, Synthesis and Biological Evaluation of Benzopyran Derivatives as KATP Channel Openers
Letters in Drug Design & Discovery Treatment of Leukoaraiosis: A Futuristic View
Current Drug Targets Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Off-Pump Coronary Artery Bypass Grafting; is it Still Relevant?
Current Cardiology Reviews Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium
Current Green Chemistry Chemical and Biological Aspects of the Genus Verbesina
The Natural Products Journal Inhibition of Renin-Angiotensin System and Advanced Glycation End Products Formation: A Promising Therapeutic Approach Targeting on Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology Functional Selectivity in Cannabinoid Signaling
Current Molecular Pharmacology Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Targeting NO Signaling for the Treatment of Osteoporosis
Current Medicinal Chemistry Involvement of Hypoxia-Inducible Factors in the Dysregulation of Oxygen Homeostasis in Sepsis
Cardiovascular & Hematological Disorders-Drug Targets The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Impaired Cerebral Autoregulation and Vasomotor Reactivity in Sporadic Alzheimer’s Disease
Current Alzheimer Research PEDF and Septic Shock
Current Molecular Medicine Drug-Induced Hypothermia in Stroke Models: Does it Always Protect?
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Food, Nutrition & Agriculture Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
Current Pharmaceutical Design